Lantheus (Nasdaq:LNTH) announced that it acquired Cerveau Technologies, a developer of a positron emission tomography imaging agent for detecting Alzheimer’s disease. Cerveau develops the MK-6240 second-generation F 18-labeled PET imaging agent. It targets Tau tangles in Alzheimer’s disease. Bedford, Massachusetts–based Lantheus intends to pay an upfront payment and potential development and commercial milestone payments. It […]
Lantheus Medical Imaging
Lantheus gains FDA clearance for bone scan AI
Lantheus Holdings (NSDQ:LNTH) announced today that it received FDA 510(k) clearance for its automated bone scan index (aBSI). The North Billerica, Mass.-based parent company of Lanthus Medical Imaging, Progenics Pharmaceuticals and Exini Diagnostics said in a news release that the clearance is for the artificial intelligence-enabled aBSI product for use on GE Healthcare’s Xeleris platform. In […]
Lantheus, Progenics complete merger
Lantheus Medical Imaging (NSDQ:LNTH) parent company Lantheus Holdings announced the completion of its merger with Progenics Pharmaceuticals. Progenics, an oncology company developing medicines and artificial intelligence-based technologies for finding, fighting and following cancer, entered into a merger agreement with Lantheus that was first announced on Oct. 2, 2019. Upon the completion of the merger, Progenics stockholders […]
Lessons learned from Lantheus CEO Mary Anne Heino
At MassMedic’s Women in Medtech event last month, Lantheus Medical Imaging CEO Mary Anne Heino spoke with MassDevice.com editor Sarah Faulkner about her career in life sciences, the power of mentorship and the necessity of courage. When Mary Anne Heino first joined Lantheus Medical Imaging (NSDQ:LNTH) in 2013, she knew admittedly very little about the […]
GE Healthcare, Lantheus launch 2nd Phase 3 trial of PET imaging agent
GE Healthcare (NYSE: GE) and Lantheus Holdings, Inc. (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. have started a second Phase 3 clinical trial of flurpiridaz 18F, an investigational agent being evaluated for the detection of coronary artery disease. Flurpiridaz18F is designed as a positron emission tomography (PET) myocardial perfusion imaging (MPI) agent. The companies […]
GE Healthcare, Lantheus ink PET imaging agent development deal
GE Healthcare (NYSE:GE) and Lantheus Holdings(NSDQ:LNTH) said today they inked a definitive license agreement to continue the Phase III development and commercialization of the investigational flurpiridaz F 18 imaging agent. The imaging agent is designed as a positron emission tomography myocardial perfusion imaging agent that the companies say may improve the diagnosis of coronary artery disease. […]
Lantheus inks deal with GE Healthcare for PET imaging agent
Lantheus Medical Imaging (NSDQ:LNTH) said today that it signed the term sheet for a deal with GE Healthcare (NYSE:GE) for the development and commercialization of a positron emission tomography myocardial perfusion imaging agent used to improve the diagnosis of coronary artery disease. According to the deal, GE Healthcare will fund a 2nd phase III trial evaluating the imaging […]
Lantheus wins FDA nod for Definity imaging agent label update
Lantheus Medical Imaging (NSDQ:LNTH) said today it won FDA approval for a label update on its Definity imaging agent which removed a contraindication related to use in patients with a known or suspected cardiac shunt. The agent is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and improve the delineation of […]
Lantheus Medical Imaging prices $40m offering
Lantheus Medical Imaging (NSDQ:LNTH) last week priced a new $40 million offering, with funds slated to pay down approximately $55 million of the outstanding principal balance under its senior secured credit facilities. In the round, North Billerica, Mass.-based Lantheus will look to float 5.2 million shares of common stock at $7.76 per share, according to an SEC […]
Lantheus deals Australian radiopharmacy supply biz to GMS
Lantheus Medical Imaging (NSDQ:LNTH) said yesterday it is selling its Australian radiopharmacy servicing business to Global Medical Solutions. As part of the deal, Lantheus and GMS entered into a long-term supply and distribution contract, with Lantheus supplying GMS and its affiliates with its products, with associated product purchase commitments. “This transaction simplifies our service and […]
The exodus of key personnel at Google’s Verily | Personnel Moves for March 29, 2016
There’s reportedly a rare exodus under way of key personnel from a Google (NSDQ:GOOG) operation, its Verily healthcare “moonshot,” with former employees blaming the mercurial leadership of CEO Andrew Conrad. A dozen top engineers, scientists and managers have departed since Verily, formerly Google Life Sciences, was launched 3 years ago, according to the Stat website. […]